|
Name |
Amestolkolide A
|
Molecular Formula | C23H24O7 | |
IUPAC Name* |
(1R,2R,10S,13R,15R,18R,19S)-7,7,13,18-tetramethylspiro[6,11,14,16-tetraoxahexacyclo[16.3.1.03,8.010,21.012,20.015,19]docosa-3,8,12(20)-triene-2,2'-oxirane]-5,17-dione
|
|
SMILES |
C[C@@H]1C2=C3[C@@H]4[C@H](O1)OC(=O)[C@@]4(C[C@@H]5C3[C@@H](O2)C=C6C(=CC(=O)OC6(C)C)[C@@]57CO7)C
|
|
InChI |
InChI=1S/C23H24O7/c1-9-18-16-15-12(7-22(4)17(16)19(27-9)29-20(22)25)23(8-26-23)11-6-14(24)30-21(2,3)10(11)5-13(15)28-18/h5-6,9,12-13,15,17,19H,7-8H2,1-4H3/t9-,12-,13+,15?,17-,19-,22-,23+/m1/s1
|
|
InChIKey |
WCTLLUQPCVNPKU-MUGZIZBGSA-N
|
|
Synonyms |
Amestolkolide A
|
|
CAS | NA | |
PubChem CID | 139590899 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 412.4 | ALogp: | -0.1 |
HBD: | 0 | HBA: | 7 |
Rotatable Bonds: | 0 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 83.6 | Aromatic Rings: | 7 |
Heavy Atoms: | 30 | QED Weighted: | 0.447 |
Caco-2 Permeability: | -5.049 | MDCK Permeability: | 0.00002630 |
Pgp-inhibitor: | 1 | Pgp-substrate: | 0.002 |
Human Intestinal Absorption (HIA): | 0.004 | 20% Bioavailability (F20%): | 0.794 |
30% Bioavailability (F30%): | 0.544 |
Blood-Brain-Barrier Penetration (BBB): | 0.572 | Plasma Protein Binding (PPB): | 87.24% |
Volume Distribution (VD): | 2.945 | Fu: | 10.48% |
CYP1A2-inhibitor: | 0.047 | CYP1A2-substrate: | 0.14 |
CYP2C19-inhibitor: | 0.588 | CYP2C19-substrate: | 0.683 |
CYP2C9-inhibitor: | 0.538 | CYP2C9-substrate: | 0.008 |
CYP2D6-inhibitor: | 0.013 | CYP2D6-substrate: | 0.069 |
CYP3A4-inhibitor: | 0.602 | CYP3A4-substrate: | 0.666 |
Clearance (CL): | 4.716 | Half-life (T1/2): | 0.36 |
hERG Blockers: | 0.387 | Human Hepatotoxicity (H-HT): | 0.794 |
Drug-inuced Liver Injury (DILI): | 0.635 | AMES Toxicity: | 0.863 |
Rat Oral Acute Toxicity: | 0.521 | Maximum Recommended Daily Dose: | 0.905 |
Skin Sensitization: | 0.912 | Carcinogencity: | 0.341 |
Eye Corrosion: | 0.004 | Eye Irritation: | 0.012 |
Respiratory Toxicity: | 0.589 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC002931 | 0.550 | D0Y2YP | 0.219 | ||||
ENC003843 | 0.532 | D0D2TN | 0.219 | ||||
ENC005628 | 0.449 | D04SFH | 0.218 | ||||
ENC005627 | 0.442 | D04GJN | 0.218 | ||||
ENC004709 | 0.397 | D0KR9U | 0.213 | ||||
ENC003925 | 0.372 | D02JNM | 0.213 | ||||
ENC003926 | 0.350 | D06AEO | 0.213 | ||||
ENC002851 | 0.340 | D0Z4ZT | 0.212 | ||||
ENC002903 | 0.318 | D0K7LU | 0.211 | ||||
ENC000924 | 0.309 | D0D2VS | 0.210 |